Prescribing patterns of medicinal cannabis for epilepsy
Evidence for the use of medicinal cannabis in epilepsy has emerged in recent years. Data on the prescribing practices of medicinal cannabis for epilepsy has not been collected to date in Ireland. This project aims to survey prescribers of medicinal cannabis for epilepsy in Ireland in 2019.
We sent an anonymous survey to all adult and paediatric consultant neurologists in the Republic of Ireland in 2019. The survey included questions regarding the product prescribed, indication, estimated efficacy, and adverse effects.
62 consultant neurologists were surveyed with 23 respondents (37%). Five (23%) of the respondents had prescribed medicinal cannabis. The most common indication was Lennox-Gastaut syndrome (3) followed by Dravet syndrome (2) and Focal Epilepsy (2). Four (80%) of the prescribers had ceased a prescription; reasons cited included: side-effects (2), lack of effect (2) and cost (1). Side effects noted included drowsiness (2), lethargy (1) and nausea (1). Efficacy was estimated at ‘no improvement’ by 2 prescribers, ‘mild improvement’ by 2 prescribers; 1 prescriber noted ‘significant improvement’.
Our survey revealed a small number of medicinal cannabis prescribers for epilepsy in the Republic of Ireland, suggesting a limited clinical exposure in the country to date. Resurvey at future intervals is recommended as product availability and familiarity increases, to guide clinical use and prescription programs.
CommentsThe original article is available at www.imj.ie
Published CitationGilligan M, Widdess-Walsh P. Prescribing patterns of medicinal cannabis for epilepsy. Ir Med J. 2021;114(10):487
Publication DateNovember/December 2021
- Beaumont Hospital
PublisherIrish Medical Association
- Published Version (Version of Record)